Page 3 - Anemia Due News Today : Breaking News, Live Updates & Top Stories | Vimarsana

- Phase 2 data demonstrate that the addition of parsaclisib to ruxolitinib (Jakafi®) resulted in spleen volume reduction and improvement in symptom burden in patients with myelofibrosis (MF) - Initial results of a Phase 1/2 study evaluating the safety and tolerability of INCB00928, an ALK2 inhibitor, show INCB00928 improves anemia in patients with MF both as monotherapy and in combination with ruxolitinib - These studies are part of our LIMBER program evaluating ruxolitinib combinations and potential new targets for appropriate patients with myeloproliferative neoplasms (MPNs)

United statesMascarenhasj hemaspherePeter langmuirAbdulraheem yacoubDrug administrationAmerican society of hematologyExchange commissionLandmark survey availableUniversity of kansas cancer centerOncology drug development incyteResearch foundationIncyte corporationThese phaseAmerican societyAnnual meetingNew orleans